GlassScriptPhysician profile
Trina Pal
NPI 1427578822
$2,701.35
in general payments reported to CMS, 2019-2025
23 companies · $1,405 in 2025
The $1,405 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $222 · 2023: $443 · 2024: $631 · 2025: $1,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,215 · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,215.18 |
| Education | $263.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $767.01 | 2022-2025 | |
| Amgen INC. | $321.06 | 2022-2025 | Evenity, Tavneos, Enbrel |
| Janssen Biotech, INC. | $298.54 | 2023-2024 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.86 | 2024-2025 | Ofev |
| Ucb, INC. | $233.57 | 2024-2025 | Bimzelx |
| Aurinia Pharma U.S., INC. | $156.42 | 2023-2025 | Lupkynis |
| Actelion Pharmaceuticals US, INC. | $80.40 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $80.00 | 2022 | |
| Mallinckrodt Hospital Products INC. | $78.29 | 2025 | Acthar |
| Grifols USA, LLC | $61.32 | 2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $59.87 | 2025 | Orenitram, Remodulin |
| Viatris Specialty LLC | $44.01 | 2025 | Yupelri |
| Kyowa Kirin, INC. | $42.99 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $41.45 | 2025 | Dupixent |
| Glaxosmithkline, LLC. | $30.79 | 2025 | Benlysta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $30.52 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $26.63 | 2024 | Orencia |
| Melinta Therapeutics, LLC | $24.74 | 2025 | Rezzayo, Orbactiv |
| Takeda Pharmaceuticals U.S.A., INC. | $19.74 | 2025 | Glassia |
| Merck Sharp & Dohme LLC | $19.24 | 2025 | Capvaxive |
| Organogenesis INC. | $19.17 | 2024 | Puraply Am |
| Baxter Healthcare | $17.90 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Organon LLC | $8.83 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trina Pal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.